Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s share price traded down 0.9% during trading on Friday . The stock traded as low as $14.04 and last traded at $14.20, with a volume of 170,564 shares trading hands. The stock had previously closed at $14.33.

Several equities analysts have commented on the company. Citigroup Inc. started coverage on Lexicon Pharmaceuticals in a research report on Tuesday, August 2nd. They issued a “buy” rating and a $21.00 target price for the company. Wedbush raised their price objective on Lexicon Pharmaceuticals from $30.00 to $31.00 and gave the stock an “outperform” rating in a research report on Friday, August 5th. Stifel Nicolaus raised their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $20.07.

The firm’s market capitalization is $1.48 billion. The firm has a 50 day moving average price of $15.46 and a 200 day moving average price of $13.48.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.04. The firm earned $20.10 million during the quarter, compared to analysts’ expectations of $12.36 million. Lexicon Pharmaceuticals’s revenue for the quarter was up 5186.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.27) earnings per share. Analysts anticipate that Lexicon Pharmaceuticals Inc. will post ($1.54) EPS for the current year.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.